Shots:
The US FDA has granted ODD to GSK’s risvutatug rezetecan (GSK5764227) for the treatment of small-cell lung cancer (SCLC)
Designation was supported by preliminary P-I (ARTEMIS-001) trial data showing durable responses in pts with extensive-stage SCLC treated with risvutatug rezetecan
GSK’227 is a B7-H3-targeted ADC developed by Hansoh Pharma for various solid tumors. GSK…
